ArticleCurrent pharmaceutical design2026
Exploring the Potential Mechanism of Smilax Glabra Roxb in Periodontitis Through Network Pharmacology and Molecular Docking.
Article in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionThis study aims to explore the potential mechanisms of Smilax Glabra Roxb (SGR) in the treatment of periodontitis using network pharmacology and molecular docking.
methodsThe active components and targets of SGR were identified using the TCMSP, STITCH, and SwissTargetPrediction databases, while periodontitis-related targets were retrieved from GeneCards, TTD, and OMIM. Overlapping targets were subjected to Protein-Protein Interaction (PPI) analysis via the STRING platform, followed by network analysis using Cytoscape software and the MCODE plugin to identify key protein targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted through the DAVID database to determine relevant biological processes and pathways. Finally, molecular docking was performed to assess the binding affinity between the key active components of SGR and critical target and pathway proteins.
resultsA total of 15 active components and 527 potential targets of SGR were identified, along with 367 targets related to periodontitis. The 75 overlapping targets were considered potential therapeutic targets. Key genes, such as IL6, IL1Β, and TNF, were identified through Cytoscape analysis. KEGG enrichment analysis indicated that the overlapping targets are primarily involved in inflammatory and metabolic pathways, including the AGE-RAGE signaling pathway, the lipid and atherosclerosis pathway, and the TNF signaling pathway. Molecular docking results showed that the key active components can stably bind to the critical targets and pathway proteins. DISCUSSION: SGR may have particular advantages in treating periodontitis in patients with systemic diseases, such as diabetes and cardiovascular conditions, but further research is needed to validate its clinical efficacy and safety.
conclusionThis study highlights the therapeutic potential of SGR in the treatment of periodontitis and elucidates its possible molecular mechanisms, offering new insights and targets for periodontitis therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.